Alteogen Creating a New Future
알테오젠은 기존 바이오 의약품보다 효능이 개선된 차세대 바이오베터와 기존 바이오 의약품과 동등한 효능을 나타내는 바이오시밀러 등을 연구개발하고 있는 기술선도 바이오기업입니다. NexP™ Fusion Technology –
알테오젠은 기존 바이오 의약품보다 효능이 개선된 차세대 바이오베터와 기존 바이오 의약품과 동등한 효능을 나타내는 바이오시밀러 등을 연구개발하고 있는 기술선도 바이오기업입니다. NexP™ Fusion Technology –
Location: South Korea
Employees: 11-50
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | Yuanta Inv... | yuantainve... |
| - | Solidus In... | solidusvc.... |
Mentions in press and media 14
| Date | Title | Description |
| 02.09.2026 | Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products | Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4 Alteogen's fourth licensing agreement signed this year further accelerating the expansion of the Hybrozyme™ platform DAEJE... |
| 05.08.2026 | Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product | Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen is eligible to receive up to US$365 million, including an upfront payment and development, re... |
| 10.06.2026 | Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026 | Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy Key Points Superior PK: Subcutaneous administration of ADCs combined with ALT-B4... |
| 25.03.2026 | Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics | - Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into... |
| 20.01.2026 | Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology | DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Te... |
| 17.09.2025 | Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9) | EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through its partner Qilu Pharmaceutical. DAEJEON, South Korea, Sept. 17, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) a... |
| 28.07.2025 | Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)' | CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea® Upon approval, EYLUXVI® will be Alteogen's second biosimilar product, following a Herceptin® bi... |
| 17.03.2025 | AstraZeneca купит EsoBiotec за $1 млрд | Компании заявили в понедельник, что AstraZeneca выплатит $425 млн авансом и может потратить еще до $575 млн на этапы разработки и нормативного соответствия. В Astra считают, платформа EsoBiotec имеет потенциал для трансформации клеточной те... |
| 12.11.2024 | AstraZeneca and Daiichi Sankyo Forge Ahead with Datopotamab Deruxtecan Amid Regulatory Shifts | In the fast-paced world of oncology, AstraZeneca and Daiichi Sankyo are navigating the complex landscape of drug approval with their latest offering, datopotamab deruxtecan (Dato-DXd). This investigational drug is aimed at treating advanced... |
| 11.11.2024 | Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology | DAEJEON, South Korea, Nov. 11, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sa... |
Show more